Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Ergosterol biosynthesis enzyme" does not refer to a single molecule but encompasses a group of enzymes responsible for the multi-step pathway leading to the synthesis of ergosterol, the principal sterol in fungal cell membranes. This pathway is unique to fungi and essential for fungal viability, regulating membrane fluidity, permeability, and functionality. The pathway involves over 20 distinct enzymes—key steps include the conversion of squalene to lanosterol and subsequent modifications, notably catalyzed by enzymes such as squalene epoxidase (*ERG1*), lanosterol 14α-demethylase (*ERG11*), and several others. The specificity and essential role of these enzymes, especially *ERG11*, make them major therapeutic targets for antifungal drug development. Inhibitors that target specific enzymes in this pathway, like azole antifungals, disrupt ergosterol production, leading to impaired membrane structure and ultimately fungal cell death. The ergosterol biosynthetic pathway is also involved in fungal pathogenicity and drug resistance, with regulatory complexity ensuring adaptation to environmental stress and treatment pressure[2][3][4][5][6][8]. Note: The submitted target "Fungal ergosterol synthesis enzyme" is a broad, non-canonical label. The correct approach is to specify individual enzymes (e.g., "Lanosterol 14α-demethylase," "Squalene epoxidase") within the ergosterol biosynthesis pathway, as each is a distinct molecular target with its own pharmacological and biological properties[2][3][6][8]. If a precise, structured record is required, please specify the individual enzyme of interest.
- Inhibition of lanosterol 14α-demethylase (by azoles), leading to depletion of ergosterol and accumulation of toxic sterol intermediates - Inhibition of squalene epoxidase (by allylamines), blocking squalene conversion in early biosynthesis - Disruption of membrane integrity (by polyenes, which bind ergosterol directly)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ergosterol biosynthesis enzyme.